Page 2 - Adjuvant Setting News Today

Experts explore neoadjuvant HER2+ breast cancer care, delve into treatment goals, predictors, and personalized approaches, and uncover insights on chemotherapy, trastuzumab, and post-op considerations.

Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.

Interim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival?

Chronic immune-related adverse events often persist years after adjuvant anti–PD-1 immunotherapy for high-risk melanoma and may require prolonged monitoring and management, researchers say.

A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.

Dr Vidula and Dr Langer review the role of oral selective estrogen receptor degraders (SERDs) in the treatment of ER+/HER2- metastatic breast cancer and what patient populations would benefit the most from treatment with oral SERDs.

A new study found that a deep-learning AI model predicted the risk for distant recurrence among patients with endometrial cancer.

The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.

The findings support the use of peritumoral lidocaine as a low-cost intervention prior to surgery for patients with early-stage breast cancer.

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.